Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Sulfasalazine

FDA-approved product (tablet, oral), marketed as Azulfidine, Azulfidine En-Tabs, S.a.s.-500 and 1 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Sulfasalazine
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Juvenile idiopathic arthritis
  • Rheumatoid arthritis
  • Ulcerative colitis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Aminosalicylic acid and similar agents
FDA pharmacologic class
Aminosalicylate FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA32.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli20.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae13.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis60.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Sulfasalazine in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.4 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.6 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Sulfasalazine with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Study of Sulfasalazine in Treating Painful Neuropathy

    NCT01667029 · start 2013-05

    Registered record
    Registry ID
    NCT01667029
    Conditions
    Painful Neuropathy
    Interventions
    Sulfasalazine; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2013-05
    Completion
    2017-08-10
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPainful Neuropathy
    InterventionSulfasalazine; placebo
    PhasePhase 2
    Registry statusTerminated

  • Active Conventional Therapy Compared to Three Different Biologic Treatments in Early Rheumatoid Arthritis With Subsequent Dose Reduction

    NCT01491815 · start 2012-12-14

    Registered record
    Registry ID
    NCT01491815
    Conditions
    Rheumatoid Arthritis
    Interventions
    Non-biological DMARD's; Cimzia; Orencia; RoActemra
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2012-12-14
    Completion
    2023-12
    Enrolment
    812

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRheumatoid Arthritis
    InterventionNon-biological DMARD's; Cimzia; Orencia; RoActemra
    PhasePhase 4
    Registry statusUnknown

  • To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET)

    NCT01709578 · start 2012-10

    Registered record
    Registry ID
    NCT01709578
    Conditions
    Rheumatoid Arthritis
    Interventions
    Sarilumab; placebo; hydroxychloroquine; methotrexate; sulfasalazine; leflunomide
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-10
    Completion
    2015-03
    Enrolment
    546

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRheumatoid Arthritis
    InterventionSarilumab; placebo; hydroxychloroquine; methotrexate +2 more
    PhasePhase 3
    Registry statusCompleted

  • Leflunomide Versus Sulfasalazine/Methotrexate in Rheumatoid Arthritis:an Ultrasound/Magnetic Resonance Imaging Study

    NCT01659242 · start 2012-07

    Registered record
    Registry ID
    NCT01659242
    Conditions
    Rheumatoid Arthritis
    Interventions
    Methotrexate plus sulfasalazine; Leflunomide
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2012-07
    Completion
    Not recorded
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRheumatoid Arthritis
    InterventionMethotrexate plus sulfasalazine; Leflunomide
    PhasePhase 4
    Registry statusTerminated

  • Effects of Methylnaltrexone in Comparison to Naloxone on Loperamide-induced Delay of the Oro-cecal, Whole-gut and Colon Transit Time.

    NCT01596764 · start 2011-05

    Registered record
    Registry ID
    NCT01596764
    Conditions
    Intestinal Obstruction
    Interventions
    Loperamide placebo; Loperamide; Colon Transit; Sulfasalazine; Placebo of MNTX and NLX; Naloxone; Methylnaltrexone
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-05
    Completion
    2012-01
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIntestinal Obstruction
    InterventionLoperamide placebo; Loperamide; Colon Transit; Sulfasalazine +3 more
    PhasePhase 1
    Registry statusCompleted

  • Sulfasalazine in Preventing Acute Diarrhea in Patients With Cancer Who Are Undergoing Pelvic Radiation Therapy

    NCT01198145 · start 2011-04

    Registered record
    Registry ID
    NCT01198145
    Conditions
    Diarrhea; Gastrointestinal Complications; Unspecified Adult Solid Tumor, Protocol Specific
    Interventions
    sulfasalazine; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-04
    Completion
    2017-07-15
    Enrolment
    87

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiarrhea; Gastrointestinal Complications; Unspecified Adult Solid Tumor, Protocol Specific
    Interventionsulfasalazine; placebo
    PhasePhase 3
    Registry statusCompleted

  • Moderate Rheumatoid Arthritis (RA) With Etanercept (Enbrel)

    NCT01313208 · start 2011-03

    Registered record
    Registry ID
    NCT01313208
    Conditions
    Rheumatoid Arthritis
    Interventions
    etanercept; Placebo; DMARD Therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2011-03
    Completion
    2013-05
    Enrolment
    210

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRheumatoid Arthritis
    Interventionetanercept; Placebo; DMARD Therapy
    PhasePhase 4
    Registry statusCompleted

  • On the Impact of Therapeutic Tumor Necrosis Factor-alpha Inhibition on Anogenital Human Papillomavirus Infection

    NCT02376478 · start 2009-12

    Registered record
    Registry ID
    NCT02376478
    Conditions
    Psoriasis; Inflammatory Bowel Diseases
    Interventions
    TNF-alpha inhibitors; Alternative/no medication; Alternative/no medication; Purine/folic acid analogues
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2009-12
    Completion
    2011-01
    Enrolment
    222

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsoriasis; Inflammatory Bowel Diseases
    InterventionTNF-alpha inhibitors; Alternative/no medication; Alternative/no medication; Purine/folic acid analogues
    PhaseNot recorded
    Registry statusCompleted

  • Efficacy and Safety of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis

    NCT01211834 · start 2009-10

    Registered record
    Registry ID
    NCT01211834
    Conditions
    Rheumatoid Arthritis
    Interventions
    tocilizumab; DMARDs; Placebo; DMARDs
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2009-10
    Completion
    2010-10
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRheumatoid Arthritis
    Interventiontocilizumab; DMARDs; Placebo; DMARDs
    PhasePhase 3
    Registry statusCompleted

  • Combination Disease-Modifying Antirheumatic Drugs (DMARDs) Versus Sulfasalazine in Inflammatory Back Pain

    NCT01040195 · start 2009-06

    Registered record
    Registry ID
    NCT01040195
    Conditions
    Seronegative Spondyloarthropathies
    Interventions
    Methotrexate, Hydroxychloroquine; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2009-06
    Completion
    2012-12
    Enrolment
    33

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSeronegative Spondyloarthropathies
    InterventionMethotrexate, Hydroxychloroquine; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Clinical Study of Tripterygium Capsule to Treat Early Ankylosing Spondylitis

    NCT00889694 · start 2008-10

    Registered record
    Registry ID
    NCT00889694
    Conditions
    Early Ankylosing Spondylitis
    Interventions
    Tripterygium; Sulfasalazine; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Unknown
    Start
    2008-10
    Completion
    2009-08
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEarly Ankylosing Spondylitis
    InterventionTripterygium; Sulfasalazine; placebo
    PhasePhase 2 / Phase 3
    Registry statusUnknown

  • Efficacy and Safety of Kunxian Capsule in Treatment Patients With Early Ankylosing Spondylitis

    NCT00953979 · start 2008-01

    Registered record
    Registry ID
    NCT00953979
    Conditions
    Ankylosing Spondylitis; Treatment
    Interventions
    kunxian capsule
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2008-01
    Completion
    2009-12
    Enrolment
    126

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnkylosing Spondylitis; Treatment
    Interventionkunxian capsule
    PhasePhase 4
    Registry statusCompleted

  • Rheumatoid Arthritis: Comparison of Active Therapies in Patients With Active Disease Despite Methotrexate Therapy

    NCT00405275 · start 2007-07

    Registered record
    Registry ID
    NCT00405275
    Conditions
    Rheumatoid Arthritis
    Interventions
    Etanercept; methotrexate; Sulfasalazine; Hydroxychloroquine; Placebo, triple; Placebo, etanercept
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2007-07
    Completion
    2012-05
    Enrolment
    353

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRheumatoid Arthritis
    InterventionEtanercept; methotrexate; Sulfasalazine; Hydroxychloroquine +2 more
    PhaseNot applicable
    Registry statusCompleted

  • Extension Study Evaluating Etanercept in Ankylosing Spondylitis

    NCT00410046 · start 2006-12

    Registered record
    Registry ID
    NCT00410046
    Conditions
    Ankylosing Spondylitis
    Interventions
    Enbrel (etanercept)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2006-12
    Completion
    2008-10
    Enrolment
    84

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnkylosing Spondylitis
    InterventionEnbrel (etanercept)
    PhasePhase 4
    Registry statusCompleted

  • Study Evaluating Etanercept and Sulphasalazine in Ankylosing Spondylitis

    NCT00247962 · start 2005-12

    Registered record
    Registry ID
    NCT00247962
    Conditions
    Ankylosing Spondylitis
    Interventions
    etanercept; sulphasalazine (SSZ)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2005-12
    Completion
    2008-02
    Enrolment
    566

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnkylosing Spondylitis
    Interventionetanercept; sulphasalazine (SSZ)
    PhasePhase 4
    Registry statusCompleted